PreventionGenetics has announced the integration of their genetic testing and interpretation services with FDNA’s Face2Gene suite of applications.
FDNA is the developer of Face2Gene, a clinical suite of next-generation phenotyping applications that facilitates comprehensive and precise genetic evaluations. Face2Gene uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic insights to improve and accelerate diagnostics and therapeutics.
The integration with Face2Gene increases the diagnostic power of PreventionGenetics’ genetic testing using artificial intelligence and computer vision technology, which highlights genetic variants that are highly correlated with disease and the patient’s clinical phenotype.
‘PreventionGenetics uses the most advanced technologies available to ensure patients of all kinds get the answers they need,’ said Dr James Weber, founder and president of PreventionGenetics.
‘With the cost of sequencing continuing to decline, and technologies like FDNA’s Face2Gene improving the insights available from testing, patients and providers are poised to benefit greatly’ added Weber.
Since the product’s inception, Face2Gene has analysed facial images of tens-of-thousands of patients for more than 2,500 syndromes, and non-facial phenotypes for more than 10,000 syndromes, linking the analysis to the disease-causing genetic variations.
‘Bringing FDNA’s artificial intelligence and facial analysis technologies to PreventionGenetics and other leading labs is facilitating a new age in precision medicine,’ said Dekel Gelbman, CEO, FDNA. ‘With this integration, clinicians can identify malfunctioning genetics for their patients faster, opening the door to therapy.’
